The Changing Treatment
Landscape of CDK4/6 Inhibitors

Cyclin-dependent kinase (CDK) 4/6 inhibitors have emerged as an appealing targeted cancer therapy of patients with hormone receptor-positive breast cancer. Prior to the availability of CDK4/6 inhibitors, standard first-line therapy for patients with HR+/HER2- mBC was single-agent endocrine therapy. Currently three new selective CDK4/6 inhibitors are in different stages of development. Also, mechanisms of resistance to CDK4/6 inhibitors, biomarker analyses to better select patients who derive the greatest benefit from CDK4/6 inhibitors, in both early and advanced settings, and more issues have been elucidated.

In this virtual joint event with Novartis – which already takes place the second time – both ABCSG and Novartis global experts will discuss the drastically changing treatment landscape of CDK4/6 inhibitors in different stages of breast cancer.

Particularly the experts will debate on hot topics such as OS data and their significance for clinical routine and therapeutic decision-making, the profiling of intrinsic subtypes and the role of selectivity. Furthermore, preclinical studies will be dissected on their efficacy, prospective research directions as well as co-targeting therapy strategies to overcome CDK4/6 inhibitor resistance through SERDS will be outlined and discussed.

This event will be approved with 3 DFP points for Medical Education from the Austrian Medical Chamber. You will receive a confirmation of participation.

We are looking forward to welcoming you virtually!

Supported by: